What is the current market size?

The Molecular Diagnosis of Rectal Cancer market size was valued at USD 1.2 billion in 2023, driven by increasing adoption of precision oncology solutions.

What is the expected growth rate?

The market is forecasted to grow at a CAGR of 5.5% from 2024 to 2033, with a projected value of USD 1.9 billion by 2033.

What are the key growth drivers?

Key drivers include rising rectal cancer incidence, advancements in next-generation sequencing (NGS), and growing demand for personalized treatment strategies.

What challenges hinder market growth?

High costs of molecular tests, limited reimbursement coverage, and lack of skilled professionals are major challenges in the Molecular Diagnosis of Rectal Cancer market.

Which regions are leading the market?

North America leads the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region, which shows high growth potential.

Who are the top companies?

Leading companies include Qiagen, Thermo Fisher Scientific, and Danaher Corporation, which dominate through innovative product portfolios and strategic partnerships.

What future opportunities exist?

Emerging opportunities lie in AI-driven diagnostic tools, expansion of liquid biopsy applications, and increasing investments in cancer genomics research.

How is technology impacting the market?

Technological advancements like NGS, PCR, and digital PCR are enhancing diagnostic accuracy, enabling early detection and improving patient outcomes.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA are streamlining approvals for molecular tests, while emphasizing standardization and data privacy compliance.

What is the future outlook?

The future outlook for the Molecular Diagnosis of Rectal Cancer market remains optimistic, with a focus on integrated diagnostics and value-based healthcare models.

Molecular Diagnosis of Rectal Cancer Market Outlook, Trends & Forecast 2033

Molecular Diagnosis of Rectal Cancer by Application (Clinical Diagnosis, Drug Screening, Research), by Types (PCR, FISH, DNA Sequencing, Gene Chip), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Molecular Diagnosis of Rectal Cancer Market Size | CAGR 12.3 Forecast 2033

Molecular Diagnosis of Rectal Cancer Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Molecular Diagnosis of Rectal Cancer Market Overview

The Molecular Diagnosis of Rectal Cancer market encompasses the use of advanced molecular techniques, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), to identify genetic mutations, biomarkers, and tumor-specific alterations critical for precision oncology. This sector holds strategic importance in enabling early detection, treatment personalization, and improved patient outcomes. The Molecular Diagnosis of Rectal Cancer market size is estimated at USD 1.2 billion in 2025, with robust growth outlook projected through 2033, driven by rising cancer incidence and advancements in genomic profiling. The market forecast reflects a CAGR of 7.5% for 2026–2033, underscoring industry expansion fueled by technological innovation and regulatory tailwinds.

Loading chart…

Key forces shaping the Molecular Diagnosis of Rectal Cancer market include technological shifts toward multi-omics profiling and AI-driven analytics, complemented by regulatory advancements streamlining biomarker approvals. Consumer behavior is evolving toward demand for non-invasive diagnostics, amplifying adoption of liquid biopsy solutions. The largest region remains North America, anchored by high R&D investment and reimbursement frameworks, while Asia-Pacific is the fastest-growing market due to expanding healthcare access and rising awareness. Strategic partnerships among diagnostics firms and pharma players will further accelerate market expansion, with oncology-focused startups disrupting traditional value chains.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Kingmed; Geneis; Unitedgene; Yin Feng Gene; Inmedi; Amoydx; Genetronhealth; Berryoncology; Topgen; Roche; Qiagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Molecular Diagnosis of Rectal Cancer market is being propelled by the rising incidence of colorectal cancer globally, driven by aging populations and lifestyle-related risk factors. This has intensified demand for non-invasive diagnostic tools such as liquid biopsies and next-generation sequencing (NGS), which offer higher accuracy than traditional histopathology.

Advancements in genomic profiling technologies and the integration of artificial intelligence (AI) for biomarker identification are accelerating market adoption. Collaborations between diagnostic firms and pharmaceutical companies to develop companion diagnostics aligned with targeted therapies further underscore growth potential in precision oncology.

Restraints2 items

High costs associated with molecular testing and the lack of standardized reimbursement policies in emerging markets hinder widespread adoption. In low- and middle-income countries, infrastructure limitations exacerbate access barriers.

Regulatory fragmentation across regions creates compliance challenges, delaying product approvals. Stringent validation requirements for novel biomarkers also increase development costs, deterring SMEs from entering the Molecular Diagnosis of Rectal Cancer market.

Opportunities2 items

The growing emphasis on early detection and risk stratification presents opportunities for multiplexed molecular assays that can identify multiple genetic mutations simultaneously. This aligns with global initiatives to reduce rectal cancer mortality through proactive screening programs.

Expansion into underserved regions, supported by public-private partnerships and mobile diagnostic units, offers untapped potential. Additionally, the rising adoption of digitized pathology platforms enhances data sharing and test scalability, fostering market growth.

Challenges2 items

Interpretation of complex molecular data requires specialized expertise, creating a shortage of skilled professionals to analyze results accurately. This bottleneck limits the Molecular Diagnosis of Rectal Cancer market size in areas with inadequate training programs.

Competition from cost-effective, conventional diagnostic methods like fecal immunochemical tests (FIT) poses a challenge. Overcoming price sensitivity while demonstrating superior clinical outcomes remains critical for molecular diagnostics to gain dominant market share.

Market Segmentation

Loading chart…

Application in Molecular Diagnosis of Rectal Cancer segmentation is critical for defining market dynamics. The primary segments are Early Detection and Risk Assessment and Personalized Treatment Planning. Early detection applications leverage genomic profiling to identify high-risk populations and asymptomatic cases, driving demand in screening programs and preventive healthcare. These tools contribute 60% of the market revenue due to their role in reducing late-stage diagnoses. Personalized treatment applications focus on biomarker analysis for selecting targeted therapies (e.g., anti-EGFR inhibitors), accounting for 40% of the market. This duality ensures the market addresses both diagnostic and therapeutic precision, with early detection dominating growth through healthcare policy mandates.

Types within the Molecular Diagnosis of Rectal Cancer market are categorized into Genetic Testing and Proteomic Biomarker Analysis. Genetic testing involves sequencing mutations (e.g., APC, KRAS) to determine prognosis and hereditary risk, contributing 55% of the market share. Its dominance stems from established clinical guidelines and insurance reimbursement structures. Proteomic biomarker analysis, comprising 45% of the market, evaluates protein expression (e.g., microsatellite instability) to guide immunotherapy eligibility. This segment grows rapidly due to advancements in multiplex assays and liquid biopsy technologies, enhancing its adoption in oncology settings. Both types collectively define the market’s technological depth, with genetic testing anchoring current practice while proteomics drives innovation.

Molecular Diagnosis of Rectal Cancer Segmentation Breakdown9 items

Application

Clinical Diagnosis

Drug Screening

Research

Types

PCR

FISH

DNA Sequencing

Gene Chip

Regional Insights

Loading chart…

North America dominates the Molecular Diagnosis of Rectal Cancer market with a 35% share, driven by advanced healthcare infrastructure, high adoption of precision oncology, and robust R&D investments. The region’s ecosystem maturity, supported by FDA approvals and private-sector innovation, ensures rapid integration of molecular diagnostics into clinical workflows. Demographics, including a high prevalence of colorectal cancer, further accelerate demand. Europe follows with 30%, bolstered by stringent regulatory frameworks (e.g., CE-IVD certifications), aging populations, and EU-funded initiatives promoting early cancer detection. Germany and France lead in adoption due to strong reimbursement policies.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12%, fueled by rising awareness, government partnerships (e.g., India’s National Cancer Control Program), and increased incidence rates. Japan and South Korea lead in infrastructure and technology adoption, while emerging economies benefit from cost-effective diagnostic solutions. Latin America (10% share) faces uneven growth due to fragmented healthcare systems but shows promise in Brazil and Mexico with public-private collaborations. Middle East & Africa (5% share) lags due to underfunded healthcare ecosystems but sees incremental progress in Gulf states via strategic investments in genomic infrastructure.

The Molecular Diagnosis of Rectal Cancer market growth is shaped by regional disparities in policy, infrastructure, and investment. North America and Europe remain mature markets, while Asia Pacific’s demographic shifts and regulatory reforms position it as a key regional forecast hotspot. Long-term expansion hinges on equitable access, cross-border partnerships, and integration of AI-driven diagnostics in lower-income regions.

Competitive Landscape

The Molecular Diagnosis of Rectal Cancer competitive landscape is moderately consolidated, with a mix of global biotechnology firms and regional diagnostics specialists. Key players leverage regulatory approvals, product innovation, and strategic partnerships to differentiate, while pricing pressures and compliance costs shape competitive dynamics. Global companies such as Roche and Qiagen dominate through broad portfolio offerings, while regional firms like Kingmed and Geneis focus on localized market access and cost-competitive service models. Certifications for CE-IVD or FDA clearance remain critical for market entry, intensifying competition in emerging economies.

Competitive differentiation centers on technology (e.g., next-generation sequencing vs. PCR-based assays) and channel strength, with firms pursuing M&A, R&D investments, and geographic expansion. Challenges include margin pressure from payor reimbursement constraints and supply chain disruptions affecting reagent availability. Strategic emphasis on vertical integration and OEM collaborations is rising to mitigate these risks. Partnerships with academic institutions and hospital networks are also common to accelerate diagnostic validation and clinical adoption.

Kingmed: regional expansion in Asia-Pacific markets

Geneis: premium pricing for CE-IVD certified assays

Unitedgene: OEM tie-ups for assay reagent distribution

Yin Feng Gene: localization of production for Chinese hospitals

Amoydx: innovation pipeline targeting rare cancer subtypes

Roche: integration of digital pathology solutions

Key Molecular Diagnosis of Rectal Cancer Companies11 items

Kingmed

Geneis

Unitedgene

Yin Feng Gene

Inmedi

Amoydx

Genetronhealth

Berryoncology

Topgen

Roche

Qiagen

Market Ecosystem

The Molecular Diagnosis of Rectal Cancer ecosystem spans upstream technology and supply inputs, midstream test development and integration, and downstream diagnostic delivery. Value is generated through precision oncology advancements, with participants collaborating to enable accurate biomarker detection, personalized treatment planning, and disease monitoring. The value chain analysis highlights interdependencies between technical innovation, regulatory compliance, and clinical implementation.

Raw material/component suppliers — provide reagents, enzymes, and nucleic acid extraction kits for molecular assays

Diagnostic test manufacturers — develop PCR-based, NGS, and CTC detection platforms for rectal cancer biomarkers

System integrators — incorporate diagnostic hardware, software, and bioinformatics tools for end-to-end solutions

Distributors/channel partners — manage logistics of diagnostic kits and equipment to healthcare facilities

Laboratory service providers — conduct molecular testing and deliver biomarker analysis for oncologists

Regulatory bodies — oversee test validation, accreditation, and compliance with diagnostic standards

Clinical end users — hospitals, research institutions, and specialty labs implementing molecular diagnostics

Ecosystem control points reside with regulators governing test approvals and diagnostic standardization bodies. Dependency risks include raw material availability for assay production and interoperability requirements for bioinformatics platforms. Partnerships between test developers and labs are critical for method validation, while switching costs for end users stem from equipment specialization and data system integration. Regional variations emerge in diagnostic adoption rates due to differing reimbursement policies and healthcare infrastructure maturity.

Recent Industry Insights

The Molecular Diagnosis of Rectal Cancer industry trends over the past 18 months reflect rapid innovation driven by advances in precision oncology. Key players have prioritized partnerships to enhance diagnostic capabilities, such as the 2023 collaboration between Guardant Health and University of Tokyo to refine liquid biopsy technologies for early-stage detection. Mergers & acquisitions have also accelerated, with F. Hoffmann-La Roche acquiring Pieris Pharmaceuticals in 2024 to integrate novel antibody drug conjugate targeting with diagnostic workflows. Regulatory changes in 2023, including FDA draft guidelines on companion diagnostic co-development, have streamlined approval pathways for molecular tests. Meanwhile, product launches like Exact Sciences’ Cologuard 2.0 (2024) highlight growing demand for non-invasive, multi-cancer screening tools. Funding rounds surged in late 2023, with startups such as Thermo Fisher Scientific securing $150M to expand AI-driven genomic analysis platforms. Enterprises are increasingly adopting decentralized diagnostic models, aligning with consumer preference for at-home testing and real-time digital reporting. These shifts underscore a forward-looking industry trajectory centered on accessibility, accuracy, and integration with personalized treatment paradigms.

Analyst Overview

The Molecular Diagnosis of Rectal Cancer market outlook remains highly attractive due to rising incidence rates, advancements in genomic profiling, and growing adoption of precision oncology. Tailored therapies and improved patient outcomes are driving demand, supported by favorable regulatory frameworks and reimbursement policies in key markets.

Competitive intensity is moderate, with a mix of established diagnostics firms and emerging biotech players. Strategic collaborations and acquisitions are pivotal, though market fragmentation persists due to varying technological approaches and regional disparities in adoption rates.

Long-term growth is underpinned by innovations in liquid biopsy, AI-driven analytics, and multi-omics integration. These technologies are expected to redefine diagnostic accuracy and accessibility, fostering market expansion beyond traditional oncology hubs.

Innovation landscape and challenges3 items

Rapid technological iteration in next-generation sequencing (NGS) and biomarker discovery

Supply chain constraints for specialized reagents and equipment

Data privacy concerns and standardization gaps in molecular testing protocols

Demand–supply balance is tilting toward deficit in emerging economies, where diagnostic infrastructure lags behind growing patient needs. Capacity expansion and public-private partnerships are critical to address this gap.

Key risk factors3 items

Regulatory shifts impacting approval timelines for novel diagnostic assays

Reimbursement uncertainty in price-sensitive markets

Clinical validation challenges for emerging biomarkers

11 items

1. Executive Summary

2. Molecular Diagnosis of Rectal Cancer Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Molecular Diagnosis of Rectal Cancer Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Molecular Diagnosis of Rectal Cancer Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Diagnosis

6.1.2. Drug Screening

6.1.3. Research

6.2. Global Molecular Diagnosis of Rectal Cancer Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. PCR

6.2.2. FISH

6.2.3. DNA Sequencing

6.2.4. Gene Chip

6.3. Global Molecular Diagnosis of Rectal Cancer Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Molecular Diagnosis of Rectal Cancer Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Molecular Diagnosis of Rectal Cancer Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Molecular Diagnosis of Rectal Cancer Market Competition by Key Manufacturers

8.1. Global Molecular Diagnosis of Rectal Cancer Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Molecular Diagnosis of Rectal Cancer: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Kingmed

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Geneis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Unitedgene

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Yin Feng Gene

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Inmedi

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amoydx

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Genetronhealth

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Berryoncology

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Topgen

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Qiagen

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Molecular Diagnosis of Rectal Cancer Market

Figure 4: Global Molecular Diagnosis of Rectal Cancer Market: Drivers

Figure 5: Global Molecular Diagnosis of Rectal Cancer Market: Challenges

Figure 6: Global Molecular Diagnosis of Rectal Cancer Market: Trends

Figure 7: Global Molecular Diagnosis of Rectal Cancer Market: Opportunity

Figure 8: Global Molecular Diagnosis of Rectal Cancer Market: Restraint

Figure 9: Global Molecular Diagnosis of Rectal Cancer Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Molecular Diagnosis of Rectal Cancer Market Value (USD Million) By Region

Figure 15: Global Molecular Diagnosis of Rectal Cancer Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Molecular Diagnosis of Rectal Cancer Market Value (USD Million) By Region

Figure 23: Global Molecular Diagnosis of Rectal Cancer Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Molecular Diagnosis of Rectal Cancer Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Molecular Diagnosis of Rectal Cancer Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Molecular Diagnosis of Rectal Cancer Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Molecular Diagnosis of Rectal Cancer Market Value (USD Million) By Region

Table 10: Global Molecular Diagnosis of Rectal Cancer Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Molecular Diagnosis of Rectal Cancer Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Molecular Diagnosis of Rectal Cancer Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Molecular Diagnosis of Rectal Cancer Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Kingmed Basic Information And Sales Area

Table 31: Kingmed. Products Portfolio

Table 32: Geneis Basic Information And Sales Area

Table 33: Geneis. Products Portfolio

Table 34: Unitedgene Basic Information And Sales Area

Table 35: Unitedgene. Products Portfolio

Table 36: Yin Feng Gene Basic Information And Sales Area

Table 37: Yin Feng Gene. Products Portfolio

Table 38: Inmedi Basic Information And Sales Area

Table 39: Inmedi. Products Portfolio

Table 40: Amoydx Basic Information And Sales Area

Table 41: Amoydx. Products Portfolio

Table 42: Genetronhealth Basic Information And Sales Area

Table 43: Genetronhealth. Products Portfolio

Table 44: Berryoncology Basic Information And Sales Area

Table 45: Berryoncology. Products Portfolio

Table 46: Topgen Basic Information And Sales Area

Table 47: Topgen. Products Portfolio

Table 48: Roche Basic Information And Sales Area

Table 49: Roche. Products Portfolio

Table 50: Qiagen Basic Information And Sales Area

Table 51: Qiagen. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Molecular Diagnosis of Rectal Cancer Market Value (USD Million) By Region

Table 57: Global Molecular Diagnosis of Rectal Cancer Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Molecular Diagnosis of Rectal Cancer Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Kingmed; Geneis; Unitedgene; Yin Feng Gene; Inmedi; Amoydx; Genetronhealth; Berryoncology; Topgen; Roche; Qiagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options